An Intronic Mutation is Associated with Prolactinoma in a Young Boy, Decreased Penetrance in his Large Family, and Variable Effects on MEN1 mRNA and Protein

Abstract

Prolactinomas are rare tumors in prepubertal children. A prolactinoma in a young child may be due to sequence variants in genes that are known to cause these tumors (MEN1, PRKAR1A, AIP). An 11-year-old boy with a macroprolactinoma was treated with cabergoline and the tumor receded. We studied the patient and his family for genetic causes of this tumor. No mutations were present in the coding sequence of PRKAR1A and AIP. A novel heterozygous substitution (IVS3-7 c>a) was identified in intron 3 of MEN1. We also found an additional PCR amplicon that incorporated the entire intron 3 of the gene (210 bp) in the patient's cDNA. The same amplicon was present with lower intensity in some of the control individuals who were not mutation carriers. Intron 3 harbors an in-frame stop codon and its incorporation is predicted to result in a prematurely terminated protein. We conclude that a novel MEN1 variation was identified in a young boy with prolactinoma and six of his relatives who did not present with prolactinoma or other MEN1 related symptoms. This novel MEN1 variation may be associated with low penetrance of the disease. The IVS3-7 c>a defect is suggested to be pathogenic because it is associated with lower menin levels in the cells of these patients, but its consequences may be mitigated by a variety of factors including changes in transcription and translation of the MEN1 gene.

Key words

genotype - menin - pituitary tumors - children - multiple endocrine neoplasia type 1

References

• 1 Webb C, Prayson RA. Pediatric pituitary adenoma.  Arch Pathol Lab Med. 2008;  132 77-80
• 2 Jagannathan J, Kanter AS, Sheehan JP, Jane  Jr  JR, Laws  Jr  ER. Benign brain tumors: sellar/paraselar tumors.  Neurol. 2007;  25 1231-1249
• 3 Ciccarelli A, Daly AF, Beckers A. The epidemiology of prolactinomas.  Pituitary. 2005;  8 3-6
• 4 Diamond  Jr  FB. Pituitary adenomas in children: development and diagnosis.  Fetal Pediatric Pathol. 2006;  25 339-356
• 5 De Menis E, Visentin A, Billeci D, Tramontin P, Agostini S, Marton E, Conte N. Pituitary adenomas in childhood and adolescence. Clinical analysis of 10 cases.  J Endocrinol Invest. 2001;  24 92-97
• 6 Beckers A, Daly AF. The clinical, pathological, and genetic features of familial isolated pituitary adenomas.  Eur J Endocrinol. 2007;  157 371-382
• 7 Daly AF, Jaffrain-Rea ML, Beckers A. Clinical and genetic features of familial pituitary adenomas.  Horm Metab Res. 2005;  37 347-354
• 8 Stratakis CA, Schussheim DH, Freedman SM, Keil MF, Pack SD, Agarwal SK, Skarulis MC, Weil RJ, Lubensky IA, Zhuang Z, Oldfield EH, Marx SJ. Pituitary macroadenoma in a 5-year-old: an early expression of multiple endocrine neoplasia type 1.  J Clin Endocrinol Metab. 2000;  85 4776-4780
• 9 Oiwa A, Sakurai A, Sato Y, Sakuma T, Yamashita K, Katai M, Aizawa T, Hashizume K. Pituitary adenomas in adolescent patients with multiple endocrine neoplasia type 1.  Endocr J. 2002;  49 635-640
• 10 Rix M, Hertel NT, Nielsen FC, Jacobsen BB, Hoejberg AS, Brixen K, Hangaard J, Kroustrup JP. Cushing's disease in childhood as the first manifestation of multiple endocrine neoplasia syndrome type 1.  Eur J Endocrinol. 2004;  151 709-715
• 11 Tala HP, Carvajal CA, Gonzales AA, Garrido JL, Tobar J, Solar A, Campino C, Arteaga E, Fardella CE. New splicing mutation of MEN1 gene affecting the translocation of menin to the nucleus.  J Endocrinol Invest. 2006;  29 888-893
• 12 Chandrasekharappa SC, Guru SC, Manickamp P, Olufemi SC, Collins FS, Emmert-Buck MR, Debelenko LV, Zhuang Z, Lubensky IA, Liotta LA, Ccrabtree JS, Wang Y, Roe BA, Weisemann J, Boguski MS, Agarwal SK, Kester MB, Kim YS, Heppner C, Dong Q, Spiegel AM, Burns AL, Marx SJ. Positional cloninig of the gene for multiple endocrine neoplasia type 1.  Science. 1997;  276 404-407
• 13 Kirschner LS, Carney JA, Pack SD, Taymans SE, Giatzakis C, Cho YS, Cho-Chung YS, Stratakis CA. Mutations of the gene encoding the protein kinase A type I-alpha regulatory subunit in patients with the Carney complex.  Nat Genet. 2000;  26 89-92
• 14 Daly AF, Vanbellinghen JF, Khoo SK, Jaffrain-Rea ML, Naves LA, Guitelman MA, Murat A, Emy P, Gimenez-Roqueplo AP, Tamburrano G, Raverot G, Barlier A, De Herder W, Penfornis A, Ciccarelli E, Estour B, Lecomte P, Gatta B, Chabre O, Sabaté MI, Bertagna X, Garcia Basavilbaso N, Stalldecker G, Colao A, Ferolla P, Wémeau JL, Caron P, Sadoul JL, Oneto A, Archambeaud F, Calender A, Sinilnikova O, Montañana CF, Cavagnini F, Hana V, Solano A, Delettieres D, Luccio-Camelo DC, Basso A, Rohmer V, Brue T, Bours V, Teh BT, Beckers A. Aryl hydrocarbon receptor-interacting protein gene mutations in familial isolated pituitary adenomas: analysis in 73 families.  J Clin Endocrinol Metab. 2007;  92 1891-1896
• 15 Neary CL, Nesterova M, Cho YS, Cheadle C, Becker KG, Cho-Chung YS. Protein kinase A isozyme switching: eliciting differential cAMP signaling and tumor reversion.  Oncogene. 2004;  23 8847-8856
• 16 Guru SC, Goldsmith PK, Burns AL, Marx SJ, Spiegel AM, Collins FS, Chandrasekharappa SC. Menin, the product of the MEN1 gene, is a nuclear protein.  Proc Natl Acad Sci USA. 1998;  95 1630-1634
• 17 Dignam JD, Lebovitz RM, Roeder RG. Accurate transcription inhibition by RNA polymerase 11 in a soluble extract from isolated mammalian nuclei.  Nucleic Acids Res. 1983;  11 1475-1489
• 18 Brunak S, Engelbrecht J, Knudsen S. Prediction of human mRNA donor and acceptor sites from the DNA sequence.  J Mol Biol. 1991;  5; 220 49-65
• 19 Dogan RI, Getoor L, Wilbur WJ, Mount SM. SplicePort–an interactive splice-site analysis tool.  Nucleic Acids Res. 2007;  35 ((Web Server issue)) W285-W291
• 20 Lemos MC, Thakker RV. Multiple endocrine neoplasia type 1 (MEN1): analysis of 1336 mutations reported in the first decade following identification of the gene.  Hum Mutat. 2008;  29 22-32
• 21 Verges B, Boureille F, Goudet P, Murat A, Beckers A, Sassolas G, Cougard P, Chambe B, Montvenay C, Calender A. Pituitary disease in MEN1 type 1 (MEN1):data from the Franch Belgium MEN1 multicenter study.  J Clin Endocrinol Metab. 2002;  87 457-465
• 22 Horvath A, Stratakis CA. Clinical and molecular genetics of acromegaly: MEN1, Carney complex, McCune-Albright syndrome, Familial acromegaly and genetic defects in sporadic tumors.  Rev Endocr Metab Disord. 2007;  9 1-11
• 23 Bowden SA, Sotos JF, Stratakis CA, Weil RJ. Successful treatment of an invasive growth hormone-secreting pituitary macroadenoma in an 8-year-old boy.  Pediatr Endocrinol Metab. 2007;  20 643-647
• 24 Howell DL, Wasilewski K, Mazewski CM, Hudgins RJ, Meacham LR. The use of high-dose daily cabergoline in an adolescent patient with macroprolactinemia.  J Pediatr Hematol Oncol. 2005;  27 326-329
• 25 Eyal O, Naffaa LN, Elder DA. A case of macroprolactinoma and elevated insulin-like growth factor-I in a young boy.  Acta Paediatr. 2005;  94 1852-1854
• 26 Agarwal SK, Kennedy PA, Scacheri PC, Novotny EA, Hickman AB, Cerrato A, Rice TS, Moore JB, Rao S, Ji Y, Mateo C, Libutti SK, Oliver B, Chandrasekharappa SC, Burns AL, Collins FS, Spiegel AM, Marx SJ. Menin molecular interactions: insights into normal functions and tumorigenesis.  Horm Metab Res. 2005;  37 369-370

Correspondence